GlassScriptPhysician profile
David O Heitter
NPI 1629045984
$2,473.95
in general payments reported to CMS, 2019-2025
25 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $563 · 2022: $768 · 2023: $506 · 2024: $240 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,142.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,240.38 | 2021-2025 | |
| Novo Nordisk INC | $186.26 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $152.07 | 2021-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $122.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $90.42 | 2022-2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $83.58 | 2022-2024 | Xtampza |
| Lilly USA, LLC | $81.70 | 2021-2025 | Kisunla, Zepbound, Mounjaro |
| Pfizer INC. | $70.56 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.63 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $47.71 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.66 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $30.32 | 2021-2022 | |
| Daiichi Sankyo INC. | $29.05 | 2022 | |
| Hologic Sales and Service, LLC | $28.79 | 2025 | Aptima |
| Nestle Healthcare Nutrition INC. | $26.31 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.25 | 2025 | Id Now Instrument |
| Sumitomo Pharma America, INC. | $23.08 | 2025 | Gemtesa |
| Amgen INC. | $20.68 | 2021 | |
| Aimmune Therapeutics, INC. | $19.93 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $19.78 | 2023 | Breztri |
| Ultragenyx Pharmaceutical INC. | $19.13 | 2022 | |
| Corcept Therapeutics | $18.01 | 2025 | Korlym |
| Mayne Pharma Commercial LLC | $16.76 | 2025 | |
| Amarin Pharma, INC. | $15.22 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Heitter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.